Sovremennyetendetsiiv lechenii kislotozavisimykh zabolevaniy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article considers the physiological mechanisms of regulation of gastric acid production; the characteristic of the modern groups of drugs used in the treatment of acid-related disorders, especially proton pump inhibitors, are described. It is emphasized that the use of modern drugs provides a high level of acid control, quality of life of patients, and the possibility of treatment in outpatient settings. The ways to improve the effectiveness and safety of pharmacological methods of correction of intensity of hydrochloric acid secretion are discussed.

Full Text

Restricted Access

References

  1. Diaz-Rubio M. Historical perspective of gastric acid inhibition. Drugs. 2005; 65(Suppl. 1): 1-6
  2. Панцырев Ю.М., Михалев А.И., Федоров Е.Д., Кузеев Е.А. Лечение язвенных гастродуоденальных кровотечений. Хирургия. 2000; 3: 21-25
  3. Fass R., Hixson L.J., Ciccolo M.L., et al. Contemporary medical therapy for gastroesophageal reflux disease. Am. Family Physician. 1997; 55: 205-18.
  4. Mandel K.G., Daggy B.P., Brodie D.A., Jacoby H.I. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment. Pharmacol. Ther. 2000; 14: 669-90.
  5. Wang Y.K., Hsu W.H., Wang S.S.W., et al. Current Pharmacological Management of Gastroesophageal Reflux Disease. Gastroenterol. Res. Pract. 2013. Epub 2013 Jun 26.
  6. Nguyen L., Birk J. Current and Prospective Pharmacotherapies in Gastroesophageal Relux Disease. Clin. Med. Ther. 2009; 1: 983-97.
  7. Сереброва С.Ю. Сравнительная клиническая фармакология современных ингибиторов протонной помпы. Дисс.. докт. мед. наук. М., 2009. 249 с.
  8. Mossner J., Caca K. Developments in the inhibition of gastric acid secretion. Eur. J. Clin. Invest. 2005; 35: 469-75.
  9. Stark H. Histamine Receptors. Biotrend Rev. 2007; 1: 1-8.
  10. Sachs G. Physiology of the parietal cell and therapeutic implications. Pharmacotherapy. 2003; 23: 68-73.
  11. Сереброва С.Ю. Омепразол или пантопразол: острые моменты дискуссии. Лечащий врач. 2013; 2: 104-08.
  12. Wessling A., Lundin D. The review of drugs against diseases caused by stomach acid - a summary. Pharm. Benefits Board. http://www.lfn.se/upload/Genomgangen/engelsk_slutrapport_magsyra_final.pdf (Accessed October 15, 2006).
  13. Galmiche J.P., Bruley Des Varannes S., Ducrotte P., et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol. Ther. 2004; 19: 655-62.
  14. Li X., Andersson T., Alstrom M., et al. Comparison of the inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities. Drug Metab. Dispos. 2004; 32: 821-27.
  15. Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC) : [сайт] [2009] URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm190825.htm (дата обращения 15.09.2013).
  16. Follow-Up to the January 26, 2009, Early Communication about an Ongoing Safety Review of Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC): [сайт] [2009] URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvid ers/DrugSafetyInformationforHeathcareProf essionals/ucm190784.htm (дата обращения 15.09.2013).
  17. Disney B.R., Watson R.D.S., Blann A.D., et al. Review article: proton pump inhibitors with clopidogrel - evidence for and against a clinically important interaction. Aliment. Pharmacol. Ther. 2011; 33: 758-67.
  18. Siller-Matula J.M., Jilma B., Schror K., et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb. Haemost. 2010; 8: 2624-41.
  19. Kwok C.S., Loke Y.K. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment. Pharmacol. Ther. 2010; 31: 810-23.
  20. De Aquino Lima J.P., Brophy J.M. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med. 2010; 8: 81.
  21. Abraham N.S., Hlatky M.A., Antman E.M., et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridenes: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J. Am. Coll. Cardiol. 2010; 56: 2051-66.
  22. Simon W.A., Herrmann M., Klein T., et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J. Pharmacol. Exp. Ther. 2007; 321(3): 866-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies